Another tyrosine kinase inhibitor (Vatalanib) was shown to inhibit VEGF-mediated angiogenesis, thus reducing tumor growth and metastasis by blocking VEGFR-1, VEGFR-2, and VEGFR-3 [24]. Here, FLT1 is linked to neoplasm.